Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


N-methyl-D-aspartate Antagonist (Ketamine) Infusion for Treatment-resistant Major Depressive Disorder With Suicidal Ideation


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT01582945

Organisation Name: Massachusetts General Hospital

Overal Status: Completed

Start Date: April 2012

Last Update: April 20, 2017

Lead Sponsor: Massachusetts General Hospital

Brief Summary: Ketamine infusion has been shown to have rapid antidepressant properties, however the possible use of ketamine in treatment-resistant depression as augmentation has not been investigated. The overall aim of this study is to assess the feasibility, safety and tolerability, efficacy and duration of the effect of intravenous N-methyl-D-aspartate antagonist ketamine as augmentation of antidepressants for chronic suicidal ideation in subjects with severe treatment-resistant depression (TRD).

This is an open-label study (pilot).

Conditions:
  • Major Depressive Disorder


Total execution time in seconds: 0.33076310157776